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Abstract
High-risk human papillomaviruses (HPVs) are the causes of many cancers, including cer-
vical, anal, vulvar, vaginal, penile and oropharyngeal. To facilitate diagnosis, prognosis
and characterization of these cancers, it is necessary to make full use of the immunolo-
gical data on HPV available through publications, technical reports and databases. These
data vary in granularity, quality and complexity. The extraction of knowledge from the
vast amount of immunological data using data mining techniques remains a challenging
task. To support integration of data and knowledge in virology and vaccinology, we de-
veloped a framework called KB-builder to streamline the development and deployment
of web-accessible immunological knowledge systems. The framework consists of seven
major functional modules, each facilitating a speciﬁc aspect of the knowledgebase con-
struction process. Using KB-builder, we constructed the Human Papillomavirus T cell
Antigen Database (HPVdb). It contains 2781 curated antigen entries of antigenic proteins
derived from 18 genotypes of high-risk HPV and 18 genotypes of low-risk HPV. The
HPVdb also catalogs 191 veriﬁed T cell epitopes and 45 veriﬁed human leukocyte antigen
(HLA) ligands. Primary amino acid sequences of HPV antigens were collected and anno-
tated from the UniProtKB. T cell epitopes and HLA ligands were collected from data
mining of scientiﬁc literature and databases. The data were subject to extensive quality
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Database toolcontrol (redundancy elimination, error detection and vocabulary consolidation). A set of
computational tools for an in-depth analysis, such as sequence comparison using BLAST
search, multiple alignments of antigens, classiﬁcation of HPV types based on cancer risk,
T cell epitope/HLA ligand visualization, T cell epitope/HLA ligand conservation analysis
and sequence variability analysis, has been integrated within the HPVdb. Predicted Class
I and Class II HLA binding peptides for 15 common HLA alleles are included in this data-
base as putative targets. HPVdb is a knowledge-based system that integrates curated
data and information with tailored analysis tools to facilitate data mining for HPV vacci-
nology and immunology. To our best knowledge, HPVdb is a unique data source provid-
ing a comprehensive list of HPV antigens and peptides.
Database URL: http://cvc.dfci.harvard.edu/hpv/
Introduction
Papillomaviruses are small double-stranded DNA viruses
that infect the squamous epithelia (skin and internal muco-
sae) of both animals and humans (1). Papillomaviruses are
diverse and species-specific. The human papillomavirus
(HPV) genome is composed of six early (E1, E2, E4, E5,
E6 and E7) Open Reading Frames (ORFs), two late (L1
and L2) ORFs and a non-coding long control region (2).
More than 170 HPV types have been characterized to date.
Of those, nearly 40 are transmitted through sexual contact,
infecting the anogenital region and the oropharynx.
Among these,  20 are designated as ‘oncogenic high risk’
because they have been linked to cervical, anal, vulvar, va-
ginal, penile and oropharyngeal cancers (3). Worldwide,
>5% of all new cancers are attributed to high-risk HPV in-
fections (4). HPV, Hepatitis B virus, Hepatitis C virus and
Helicobacter pylori were responsible for 1.9 million cancer
cases worldwide in 2008 (5). HPV is the cause of virtually
all cases of cervical cancer, the third most common female
cancer globally (6). The high-risk type HPV16 alone is re-
sponsible for 50% of cervical cancers and high-grade cer-
vical intraepithelial lesions (7). Furthermore, in the
developing world where HPV disease burden is the great-
est, cervical carcinoma is the leading cause of cancer mor-
tality among women.
Two prophylactic HPV L1 VLP (virus-like particle) vac-
cines have been developed to provide protection against in-
fection for at least 5 years and reduce the risk of cervical
cancer (8). Gardasil, an HPV quadrivalent recombinant
vaccine that is a mixture of VLPs derived from the L1 cap-
sid proteins of HPV types 6, 11, 16 and 18, was approved
by the US Food and Drug Administration in 2006 (9).
Cervarix, a prophylactic vaccine composed of a mixture of
VLPs derived from the L1 capsid proteins of HPV types 16
and 18 has been shown to be 100% effective in preventing
HPV strains 16 and 18 (10). T cells naturally eliminate the
majority of HPV infections by recognizing epitopes dis-
played on the virally altered epithelium. Therapeutic HPV
vaccines aim to treat established HPV infections and
HPV-associated malignancies by targeting non-structural
oncogenic proteins E6 and E7 (11). A recent vulvar intrae-
pithelial neoplasia clinical trial showed promising results.
Kenter et al.( 12) reported a vaccination using synthetic
long peptides spanning the complete sequence of the
HPV16 E6 and E7 oncoproteins and a conventional
adjuvant-induced clinical responses and relief of symp-
toms in 60% of the patients with high-grade vulval intrae-
pithelial neoplastic disease. However, most trials of
therapeutic HPV vaccines have yielded disappointing clin-
ical results (11).
Available immunological data related to HPV vary in
granularity, quality and complexity and are stored in vari-
ous formats, from publications, technical reports and gen-
eral-purpose databases. The challenge is to collect the data
scattered in these resources, clean, annotate, store and ana-
lyse them to facilitate meaningful knowledge discovery. To
bridge the gap between data and knowledge, we developed
a framework called KB-builder to streamline the develop-
ment and deployment of web-accessible immunological
knowledge bases. The KB-builder framework is generic
and can be applied to any immunological sequence data
set. We developed the Human Papillomavirus T cell
Antigen Database (HPVdb) using KB-builder to support
the discovery of T cell-based HPV vaccine targets and
reported it at the Association for Computing Machinery -
Conference on Bioinformatics, Computational Biology and
Biomedical Informatics (ACM-BCB) 2013 (13). We
updated and improved HPVdb by expanding the data sets
and integrating more advanced analysis tools such as anti-
gen sequence variability analysis tool based on Shannon
entropy calculation and conservation analysis of T cell epi-
topes and human leukocyte antigen (HLA) ligands. HPVdb
integrates curated data and information with tailored ana-
lysis tools to facilitate data mining and to aid rational
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available at http://cvc.dfci.harvard.edu/hpv/.
Material and Method
KB-builder
The framework, KB-builder, consists of seven major func-
tional modules, each facilitating a specific aspect of the
database construction process. The input to the framework
is data scattered in primary databases and scientific litera-
tures. As shown in Figure 1, the modules enable automated
data collection and integration, semi-automated data
cleaning and annotation, automated data storage and
retrieval, fast deployment of basic computational tools,
development and integration of advanced tools for an
in-depth analysis of various structural and functional
properties associated with immune responses and vaccine
development, definition of workflows to answer specific
research questions and semi-automated update and
maintenance. The KB-builder framework helps set up a
web-accessible knowledgebase and the corresponding ana-
lysis pipeline within a short period (typically within 1–2
weeks), given a set of annotated genetic or protein sequen-
ces. In addition to the HPVdb, using KB-builder, several
other prototype knowledge bases have been built including
TANTIGEN: Tumor T cell Antigen Database (cvc.dfci.
harvard.edu/tadb), FLAVIdB: Flavivirus Antigen Database
(14) and FLUKB: Flu Virus Antigen Database
(research4.dfci.harvard.edu/cvc/flukb/). A workflow is an
automated process that takes a request from the user,
performs complex analysis by combining data and tools
Figure 1. Schematic overview of the KB-builder framework.
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hensive report (15). Several workflows have been imple-
mented in FLAVIdB and FLUKB to answer various
research questions, such as the identification of broadly
protective viral vaccine targets (14). The web interface of
these online knowledge bases uses a set of graphical user
interface forms with a combination of Perl, PHP, CGI and
C background programs. Development was carried out in
the CentOS 4.5 Linux environment.
Data collection
Eight HPV proteins are included in the HPVdb, namely,
E1, E2, E4, E5, E6, E7, L1 and L2. Eighteen HPV geno-
types (16, 31, 33, 35, 52, 58, 18, 39, 45, 59, 68, 26, 51,
82, 73, 53, 56 and 66) of five HPV species (HPV16,
HPV18, HPV26, HPV34 and HPV53) were annotated as
the high-risk group in HPVdb. Eighteen HPV genotypes
(11, 44, 55, 40, 91, 32, 42, 54, 61, 72, 81, 83, 84, 62, 87,
89, 71 and 64) of six HPV species (HPV6, HPV7, HPV32,
HPV54, HPV61, HPV71 and one unclassified species)
were classified as the low-risk group. Names, full names,
virus genotypes, UniProt review status, sequence status and
primary amino acid sequences of HPV antigens from the
aforementioned 36 genotypes were collected from the
UniProtKB (16). Primary amino acid sequences of HPV
were collected via database search against the UniProtKB
using the NCBI taxonomic identifiers of the 18 HPV geno-
types, for example, 333760 is the taxonomic identifier of
organism ‘HPV type 16’.
HPV T cell antigens were collected based on experimen-
tally characterized T cell epitopes and/or HLA ligands. The
criteria for the selection of HPV T cell antigens require
that the antigen must be presented via one or more HLA
alleles or be recognized by T cells. If the peptides were able
to stimulate T cell function, they are called ‘T cell epi-
topes’. If the peptides had only been tested for their binding
affinities to HLA molecules and not for T cell reactivity,
these peptides are called ‘HLA ligands’. Collection of T
cell epitopes and HLA ligands was derived from mining of
scientific literature in PubMed using the term ‘HPV AND
(T cell epitope OR HLA binding peptide)’ as a keyword
and from the Immune Epitope Database (IEDB) (17).
Data annotation and organization
The collected data and information were manually
checked. Errors, inconsistencies, ambiguous and conflict-
ing information and duplications were corrected or
removed. Sequences containing ambiguous amino acids,
such as XGXXNGILW, were removed because they make
it impossible to perform computational prediction for
HLA binding motifs. If multiple UniProt entries have iden-
tical sequences, only one entry is kept. If a UniProt entry
sequence is a substring of a longer sequence, the entry
is removed and the entry with longer sequence is kept.
The semi-structured annotated data were automatically
transformed in a unified extensible markup language
(XML) format because XML is inherently semi-structured
and is suitable for hosting semi-structured data. Three
XML files were created for HPVdb containing information
on antigens, T cell epitopes and HLA ligands. Information
in an HPV antigen record includes antigen name, full
name, virus genotype, UniProt ID, UniProt review status,
amino acid sequences, as well as T cell epitopes and HLA
ligands, if reported.
Data classification
In HPVdb, HPV viruses were classified into two groups
based on high and low clinical risk for cancer. Each risk
group was further subclassified using the virus classifica-
tion system suggested by the International Committee on
Taxonomy of Virus (ICTV). An interactive diagram pre-
sents the classification and facilitates database search by
clicking on any of the genotype boxes (Figure 2).
Database construction
The HPVdb was constructed using KB-builder, an in-house
developed framework that streamlines the development
and deployment of web-accessible immunological know-
ledge bases. The web interface uses a set of graphical user
interface forms with a combination of Perl, PHP, Common
Gateway Interface (CGI) and C background programs.
Basic analysis tools
Several basic bioinformatics tools were integrated in the
HPVdb, including a keyword search tool to locate HPV
antigens, a keyword search tool to locate the T cell epi-
topes or HLA ligands of interest and Basic Local
Alignment Search Tool (BLAST) that enables sequence
similarity search (18) and multiple sequence alignment
(MSA) to compare multiple sequences. Beyond the basic
utility of keyword search, the HPVdb also offers options
for filtering HPV antigen data based on genotype, proteins,
UniProt review status (reviewed or unreviewed) and se-
quence type (complete or fragment sequence). To search
for T cell epitopes or HLA ligands, users may input either
an epitope/ligand sequence or an HLA allele of interest in
the text box. If nothing is input into the text box, the
search result page will show all the T cell epitopes and
HLA ligands in the database. To facilitate sequence
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were organized into FASTA format and were converted
into a searchable format to enable searching using the
Basic Local Alignment Search Tool (BLAST) algorithm
(18). MAFFT, an MSA tool, selected because of its out-
standing performance in terms of speed and alignment
quality, was downloaded and installed locally (19).
Specialized analysis tools
The HLA binding prediction tool for on-the-fly peptide
binding prediction to 15 frequent HLA class I and class II
alleles (A*0101, A*0201, A*0301, A*1101, A*2402,
B*0702, B*0801, B*1501, DRB1*0101, DRB1*0301,
DRB1*0401, DRB1*0701, DRB1*1101, DRB1*1301,
DRB1*1501) has been integrated in each HPV antigen
record to facilitate efficient antigenicity analysis.
NetMHCpan and NetMHCIIpan (20, 21) were selected
for this purpose based on our previous benchmark studies
on the accuracy of online HLA binding prediction servers
(22, 23). Other data mining tools include the sequence
variability analysis tool, the conservation analysis tool for
T cell epitopes and HLA ligands and the visualization tool
that shows the localization of epitopes in a given individual
or aligned HPV protein/genotype combination. Sequence
variability analysis can be performed on entries grouped by
protein and further narrowed down by virus genotype or
subtype and sequence type. The variability analysis at
amino acid level is based on calculation of Shannon
entropy (24) at each position in an MSA. The entropy is
calculated using the formula
HðxÞ¼ 
X I
i¼1
PiðxÞlog2ðPiðxÞÞ ð1Þ
where H is the entropy, x is the position in the MSA, i rep-
resents individual amino acids at position x, I is the num-
ber of different amino acids on position x and Pi is the
frequency of the given amino acid. Conservation of a pos-
ition, x, is defined by the frequency of the consensus amino
acid.
Semiautomated update and maintenance
The database will be actively maintained by members of
the bioinformatics core, cancer vaccine center, the Dana-
Farber Cancer Institute. Bugs and problems will be fixed as
they are reported. The database will be updated every
Figure 2. Classiﬁcation of the viruses in the HPVdb based on cancer risk was done using the virus classiﬁcation system suggested by the ICTV.
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(http://www.gnu.org/software/wget/) and data from pri-
mary databases such as the Uniprot and the IEDB.
Programs have been made to automatically compare the
collected data with the existing data in the database and
identify new data; the new data will be manually anno-
tated; and the XML data files will be automatically updated
to include the annotated new data. On completion of the
data update, the last step of the database update is to test
all the basic and advanced analysis tools and workflows to
ensure they function well with the updated data files.
Results
Using the NCBI taxonomic identifiers of the 18 HPV gen-
otypes to search the UniProtKB, we collected 5099 antigen
entries (as of December 2013), of which 162 entries were
reviewed by UniProt experts and 4937 entries were not re-
viewed. The data cleaning process removed 2318 antigen
entries—5 entries had unknown gene names such as ‘X’
(UniProt ID: Q705E1) and ‘Y’ (UniProt ID: Q705E0), 83
antigen sequences contained ambiguous amino acid X and
2230 had redundant sequences. The final list has 2781
antigen entries (Table 1). Eight HPV proteins were
included in the HPVdb, namely, E1, E2, E4, E5, E6, E7, L1
and L2. A large number of antigen sequences have been re-
ported for proteins E1 (630), E2 (320), E6 (419), E7 (233),
L1 (624) and L2 (296). Around one-third of these
sequences were derived from species HPV16 (978). We
observed that inconsistent letter case has been used in gene
names. For example, gene names e7 (UniProt ID:
Q9DIH6) and I2 (UniProt ID: Q9DHD4) were listed in-
stead of E7 and L2. All lower case gene names were modi-
fied to upper case. In total, 191 verified T cell epitopes and
45 verified HLA ligands were collected from data mining
of literature and databases.
Using the keyword search function of HPVdb, users are
able to search antigen records by keywords. Users can fur-
ther refine the search by selecting a protein name, and/or a
virus genotype, and/or a sequence type and/or UniPort re-
view status. Figure 3A shows the HPVdb antigen search
page with parameters selected being Protein E7, virus
genotype 18, complete sequence regardless of UniProt
review status. Figure 3B shows the search result table.
The accession numbers in the first column are hyperlinked.
By clicking on HPV000092, we get a page, as shown
in Figure 3C, displaying information on the antigen.
The antigen information table consists of HPVACC
(a unique accession number), date, last updated date, anti-
gen name, full name, virus genotype, UniProt ID, UniProt
status (reviewed or unreviewed), sequence status (complete
or fragment), a list of T cell epitopes and HLA ligands of
the antigen with references, antigen amino acid sequence
and the embedded HLA binding prediction tool. The T-cell
epitope and HLA ligand sequences are hyperlinked to T
cell epitope or HLA ligand record tables. Most of the
epitope and HLA-ligand records were enriched with
additional annotation, e.g. ‘defined in healthy donors’,
‘associated with virus clearance’, ‘defined in cervical intra-
epithelial neoplasia (CIN) or cervical cancer patients’ and
‘defined by mass spectrometry from cervical cancer biopsy
specimens’. Most of these peptides were derived from the
two oncogenic proteins E6 and E7 of HPV16.
Users can also search T cell epitopes and HLA ligands
by keywords, such as epitope/ligand sequences or HLA
allele names. Figure 4A is a screen shot of a T cell epitope
record table—an A*0201 restricted T cell epitope in HPV
type 16 E7 protein sequences. We can learn how conserved
the epitope YMLDLQPET is by clicking on the button
‘check conservation of T cell epitope T000125’. As shown
in Figure 4B, the epitope exists in all but one HPV type 16
E7 proteins (94.12% conserved).
Figure 5A shows the sequence variability analysis tool
page. The search parameters include virus genotype 16,
protein E7 and complete sequence type. Figure 5B shows
the sequence variability analysis result page. On top of the
page, there is a plot of entropy (red curve) and percentage
of sequences (blue curve) containing the consensus amino
acid at position. The consensus sequence is shown below
X-axis with conserved positions in blue. A conserved
position is one with entropy <1, gap fraction <0.1 and
consensus amino acid >90%. The detailed position-by-
position amino acid variability information and the con-
sensus sequence are available for download.
BLAST was integrated into the database to enable
sequence similarity search. It can be used for protein and
genotype identification. The MSA can be performed by
selecting a protein name and virus genotype for sequence
diversity analysis. The visualization tool provides three
peptide display formats for mapping T cell epitopes or
HLA ligands. In format 1, T cell epitope and HLA ligands
are highlighted on the peptide sequences. In format 2, the
peptides are highlighted in the MSA. In format 3, each pep-
tide is shown in a separate line based on the restricting
HLA alleles.
Table 1. The number of antigen entries in HPVdb grouped by
their UniProt review status and type of antigen sequences
Sequence Type Reviewed Not reviewed Total
Complete sequence 160 1684 1844
Fragment 2 935 937
Total 162 2619 2781
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HPVdb and their uniform resource locators (URLs) to
access them directly. More information of the HPVdb and
instructions for using the database are available at http://
cvc.dfci.harvard.edu/hpv/HTML/help.php.
A Case Study—The Identification of a
Conserved HPV16 E7 T Cell Epitope
Because HPV proteins E6 and E7 are functionally required
for cancer initiation and persistence, they offer exceptional
Figure 3. Screenshots of HPV antigen search tool and result pages. (A) HPV antigen search page. (B) The search result page—the accession numbers
in the result table are hyperlinked to HPV antigen information pages. (C) HPV00092 (UniPort ID: P06788) information table.
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mass spectrometry, an E7-derived cytotoxic T cell epitope
(E711–19) that was presented by cervical cancer cell lines as
well as seven of nine HPV16-positive primary tumor cer-
vical cancer biopsy samples (25–27). Our analyses have
shown that the number of distinct cytotoxic T lymphocyte
epitope targets on a tumor is small, requiring precise focus-
ing of vaccine formulation. In the study, we identified the
E711–19, but not the related E711–20 peptide, on all of the
established HPV16 tumor cell lines (25). The latter
Figure 4. (A) A screenshot of a T cell epitope record table in the HPVdb. This table catalogs the relevant information of T cell epitope T000125, i.e. epi-
tope sequence, restricted HLA allele, PubMed id(s) of the reference paper(s) and its characteristics (e.g. information on how the epitope was identi-
ﬁed). A multiple sequence alignment of the protein sequences containing the epitope (highlighted) is displayed. (B) A screenshot of the conservation
analysis result page obtained by clicking on ‘check conservation of T cell epitope T000125’ button.
Database, Vol. 2014, Article ID bau031 Page 8 of 12Figure 5. (A) A screenshot of sequence variability analysis tool page. (B) Plot of entropy (red curve) and percentage of sequences (blue curve) contain-
ing the consensus amino acid. The consensus sequence is shown below X-axis with conserved positions in blue. A conserved position is one with:
entropy <1, gap fraction <0.1 and consensus amino acid >90%.
Table 2. The analysis tools integrated in HPVdb and their URLs
Tool URL References
BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi (18)
MAFFT MSA http://www.ebi.ac.uk/Tools/msa/mafft/ (19)
NetMHCpan http://www.cbs.dtu.dk/services/NetMHCpan/ (20)
NetMHCIIpan http://www.cbs.dtu.dk/services/NetMHCIIpan/ (21)
Search tool for HPV antigens http://cvc.dfci.harvard.edu/hpv/HTML/search.php
Search tool for T cell epitope/HLA ligand http://cvc.dfci.harvard.edu/hpv/HTML/searchT.php
Blast HPVdb http://cvc.dfci.harvard.edu/hpv/HTML/blast.php
MSA of HPV sequences http://cvc.dfci.harvard.edu/hpv/HTML/alignment.php
Sequence variability analysis tool http://cvc.dfci.harvard.edu/hpv/HTML/varability.php (14)
T cell epitope/HLA ligand visualization tool http://cvc.dfci.harvard.edu/hpv/HTML/viewEpitope.php
Classiﬁcation of the viruses based on cancer risk http://cvc.dfci.harvard.edu/hpv/HTML/classiﬁcation.php
HLA binding prediction tool Embedded in each antigen entry table
T cell epitope/HLA ligand conservation analysis tool Embedded in each experimentally validated T cell epitope/HLA
entry table; also embedded in each HLA binding
prediction result page.
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literature as a possible tumor antigen, was incorrectly se-
lected for vaccine formulation and was clinically ineffect-
ive (28). The two patients that did not display E711–19
peptide also had a loss of the human cellular thioreductase
GILT protein. Thioreductases are proteins that unfold cys-
teinylated proteins such as HPV E7, which was associated
with altered HPV peptidome display in HPV16-driven cer-
vical cancers (26).
The HPVdb played an important role to facilitate and
speed up the study. First, in silico predictions of A*0201
binding peptides (both 9- and 10-mers) were performed
(prediction result is not shown). Based on the prediction re-
sults, we synthesized 21 peptides. A*0201 binding assay
identified 10 of them as binding peptides. Interferon c (IFN
c) ELISpot assay was used to test immune recognition of
the 10 A*0201-binding peptides in peripheral blood mono-
nuclear cells isolated from six A*0201-positive healthy
donors. There are only two HPV peptides, E711–19 and
E629–38, eliciting spot-forming unit numbers 4- to 5-fold
over background in one donor. MS
3 Poisson detection
mass spectrometry identified that the peptide E711–19 (refer
to Figure 4A for the epitope’s information) is physically
displayed on HPV16-transformed, A*0201-positive cells.
Given the expression of E711–19 on HPV-16 transformed
or transfected cell lines, we would like to know whether
known strains of HPV16 conserve this epitope. We per-
formed the epitope conservation analysis using the analysis
tool embedded in each HPVdb T cell epitope entry page as
shown in Figure 4A. As shown in the analysis result page
in Figure 4B, the epitope is conserved in 16 of 17 (94.12%
conserved) HPV16 E7 complete sequences. A single substi-
tution mutation L15V in HPV001854 (UniProt ID:
C0KXQ5) resulted in the immune escape. Among the 35
HPV16 cervical cancer or cervicitis patients we analyzed,
only a single patient sample contained the HPV001854 se-
quence variant. Conserved HPV T cell epitopes displayed
by HPV transformed tumors such as E711–19 may be the
basis of a therapeutic T cell-based cancer vaccine.
DISCUSSION
HPV infection is prevalent among sexually active popula-
tion. However, >95% of infections are temporary and are
promptly cleared by the immune system (29, 30). The re-
gression of tumor lesions and persistent high-risk infections
depend on strong localized antigen-specific T cell responses
(31). HPV-associated cancers express viral oncoproteins,
and they represent ideal ‘non-self’ cancer antigens for the
development of a therapeutic cancer vaccine (11). One of
the research interests of our group at the Dana-Farber
Cancer Institute is the discovery of T cell-based HPV
vaccine targets. We have identified, by mass spectrometry,
an E7-derived cytotoxic T cell epitope (E711–19) that was
presented by cervical cancer cell lines as well as seven of
nine HPV16-positive primary tumor cervical cancer biopsy
samples. With the data analysis and knowledge discovery
capacity provided by the HPVdb, this epitope was found to
be highly conserved among HPV16 strains. The informa-
tion and knowledge derived through the computational
analysis enabled by the HPVdb directly added to the poten-
tial clinical value of this epitope as a vaccine candidate. It
highlights the importance of organized epitope information
across various HPV types and strains for researchers in the
field.
Several data sources provide information on HPV gen-
omic and protein sequences. The HPVdb (http://ncv.unl.
edu/Angelettilab/HPV/Database.html) was constructed a
decade ago and has not been actively maintained (32). The
Papillomavirus Episteme (PaVE) hosts 241 annotated pap-
illomavirus genomes, 2245 genes and regions, 2004 pro-
tein sequences and 47 protein structures (http://pave.niaid.
nih.gov/)( 33). The PaVE provides basic bioinformatics
tools to facilitate keyword and BLAST search, MSA and
protein structure viewing. An external L1-specific typing
tool developed by Piet Maes et al.( 34) are integrated to the
database to predict whether a new isolate is different from
other named viruses and meets the criteria for a new type.
The Human Papillomavirus Proteome Database hosts gen-
omic and proteomic information on 150 HPV strains and
their 1036 protein sequences and 743 predicted structures
(35). The HPVdb was developed with a different purpose
in mind, to facilitate data mining for HPV vaccinology and
immunology. The HPVdb tightly integrates curated
data and information on both antigen sequences and
immunological epitopes with tailored analysis tools to aid
rational vaccine design by discovery of vaccine targets. It is
a unique data mining system for knowledge discovery
in HPV with applications in T cell immunology and
vaccinology.
To support T cell epitope discovery and make use of
existing information and knowledge, we developed KB-
builder, a framework that streamlines the development
and deployment of web-accessible immunological know-
ledge systems. The KB-builder framework aims to speed up
the immunological research and vaccine design by provid-
ing specialist knowledge bases that host cleaned, well-
annotated and structured data suitable for the discovery of
new knowledge. We built several prototypes focusing
mainly on viral and tumor antigens using this framework
for immunological knowledge discovery. Knowledge bases
generated using KB-builder enable data mining using
defined workflows. User-friendly analysis tools can be
used individually or as part of workflows. The main
Database, Vol. 2014, Article ID bau031 Page 10 of 12purpose of vaccine knowledge bases is to help identify key
experiments and reduce the overall number of required
experiments for vaccine research including the discovery
and design.
Systematic discovery of HPV vaccine targets relies
heavily on the availability of accurate, up-to-date and
well-organized antigen data. HPV antigen data are avail-
able through publications, technical reports and databases.
These data vary in granularity and quality and are in vari-
ous formats. The extraction of knowledge from the data
scattered around using data mining techniques remains a
challenging task. HPVdb is a specialized bioinformatics
database that tightly integrates the content (data) and ana-
lysis tools to enable the automation of complex queries
and data mining. The HPVdb enables speed up of rational
vaccine design by providing accurate and well-annotated
data coupled with tailored computational analysis tools.
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